Price
$1.35
Increased by 0.00%
Dollar Volume (20D)
12.33 K
ADR%
5.43
Earnings Report Date (estimate)
Mar 28, 23 (N/A)
Market Cap.
59.09 M
Shares Float
17.17 M
Shares Outstanding
43.77 M
Beta
0.05
Price / Earnings
-0.71
BPR
170.36
20D Range
1.30 1.59
50D Range
1.21 1.61
200D Range
0.90 2.10
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 28, 23 -1.55 -0.40
Decreased by -718.75%
Mar 31, 21 -1.55 -0.40
Decreased by -718.75%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 22 8.42 M - -51.15 M -
Decreased by -607.32%
-
Dec 31, 20 170.50 K - 13.20 M -
Increased by +7.74 K%
-
Sep 30, 20 0.00 - -11.41 M -
Decreased by N/A%
-
Dec 31, 19 480.00 K - -4.52 M -
Decreased by -942.59%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.